Top Page
TOT BIOPHARM International Co. Ltd.
(1875)
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07B | 1.10B | 780.63M | 442.18M | 76.33M | 22.49M |
| Gross Profit | 758.56M | 782.43M | 573.99M | 370.62M | 27.47M | 15.53M |
| EBITDA | 43.83M | 84.96M | 10.45M | -5.41M | -224.51M | -254.71M |
| Net Income | 7.26M | 34.76M | -37.76M | -49.92M | -261.22M | -288.50M |
Balance Sheet | ||||||
| Total Assets | 1.48B | 1.51B | 1.43B | 1.26B | 710.26M | 641.18M |
| Cash, Cash Equivalents and Short-Term Investments | 383.98M | 381.26M | 351.60M | 517.63M | 155.38M | 225.53M |
| Total Debt | 397.20M | 395.47M | 345.65M | 289.53M | 208.56M | 7.41M |
| Total Liabilities | 744.74M | 779.12M | 739.41M | 546.59M | 375.17M | 58.83M |
| Stockholders Equity | 731.68M | 729.65M | 686.69M | 713.88M | 335.09M | 582.36M |
Cash Flow | ||||||
| Free Cash Flow | 48.42M | -7.17M | -146.77M | -180.19M | -290.45M | -285.30M |
| Operating Cash Flow | 123.43M | 116.40M | 56.43M | 59.93M | -175.14M | -263.12M |
| Investing Cash Flow | -80.23M | -122.50M | -164.10M | -282.76M | -108.39M | 12.53M |
| Financing Cash Flow | -7.09M | 34.18M | 38.23M | 481.24M | 212.08M | -61.71M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
TOT BIOPHARM International Co. Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$1.93B | 238.10 | 0.99% | ― | 9.41% | -32.69% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$1.85B | -6.12 | -14.84% | ― | -38.38% | -22.12% | |
46 Neutral | HK$1.38B | -3.89 | -67.27% | ― | ― | 47.42% | |
45 Neutral | HK$2.27B | -76.39 | -25.72% | ― | 178.36% | 86.74% | |
44 Neutral | HK$1.45B | -14.99 | -14.87% | ― | ― | 22.65% | |
43 Neutral | HK$1.71B | -6.43 | ― | ― | ― | 27.90% |
TOT BIOPHARM International Co. Ltd. Corporate Events
BioDlink International Company Limited has issued a supplemental announcement to its 2024 annual report, providing additional details on its Pre-IPO Share Option Scheme and related equity incentive plans as required under Hong Kong listing rules. The company disclosed that up to 16,969,000 shares, representing about 2.20% of its issued share capital at the annual report date, may be issued under the Pre-IPO scheme, clarified eligibility (employees and former employees acting as consultants), vesting conditions tied to seniority and R&D milestones, option exercise procedures, and the pricing mechanism, including adjustments for changes in share capital and dividends. It also confirmed that the grant period for the Pre-IPO scheme has expired, meaning no new options can be issued under it, signaling a shift toward its newer restricted share award schemes and offering investors greater transparency on dilution and long-term incentive alignment with the company’s research-focused performance targets.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited, a Hong Kong-incorporated company listed on the Hong Kong Stock Exchange (stock code 1875), announced the composition of its board, comprising an executive director, a non-executive director and three independent non-executive directors. The company has requested a halt in trading of its shares on the Hong Kong Stock Exchange from 9:00 a.m. on 29 December 2025, pending the release of an announcement containing inside information, signaling that potentially price-sensitive developments are forthcoming and placing investors temporarily in a holding pattern until further disclosure is made.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited has granted 13,350,000 restricted share awards, equivalent to about 1.73% of its issued share capital, to eight non-director employees under its 2024 Restricted Share Award Scheme. The awards, priced at HK$0.6 per share compared with a market price of HK$2.03 at the grant date, will vest in four equal tranches subject to performance targets tied to CDMO revenue and group EBITDA for 2026–2027 and multi‑year service conditions, reflecting management’s use of equity incentives to align key staff with the company’s medium‑term growth and profitability objectives, particularly in its CDMO business, although the scheme does not include a broader clawback mechanism beyond forfeiture on dismissal or misconduct.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited, along with its subsidiaries, operates in the biotechnology sector, focusing on the development and commercialization of biopharmaceutical products. The company is listed on the Hong Kong Stock Exchange and has a significant shareholder, Center Laboratories, Inc., listed on the Taipei Exchange. The company announced a 23% decrease in revenue for the nine months ending September 30, 2025, compared to the same period in 2024, due to increased market competition for its self-developed products. This financial update, extracted from unaudited management accounts, highlights fluctuating operational results, advising shareholders and investors to exercise caution.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited announced changes in its leadership, with Dr. Liu and Ms. Yeh-Huang resigning from their respective positions due to family reasons. This reshuffling may impact the company’s strategic direction and governance, as it involves key roles such as the executive director, chief executive officer, and members of the Strategy and ESG Committee.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited, a Hong Kong-based company, announced significant changes in its leadership structure. Mr. Fu, Shan has been re-designated from a non-executive director to an executive director, continuing his role as chairperson of the Board and various committees. This change positions Mr. Fu to lead and oversee the management and development of the company, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
BioDlink International Company Limited, incorporated in Hong Kong, has announced changes to its board of directors and the composition of its board committees. Effective from October 11, 2025, Mr. Fu Shan will serve as the Chairperson of the Strategy and ESG Committee, while Dr. Liu Weidong, Ms. Sun Hui, Mr. Zhang Qing, and Dr. Gu Xuelin will take on various roles across the Audit and Connected Transactions Review, Remuneration, and Nomination Committees. These changes are expected to enhance the governance and strategic oversight of the company.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.